Literature DB >> 17299039

Drying a tuberculosis vaccine without freezing.

Yun-Ling Wong1, Samantha Sampson, Willem Andreas Germishuizen, Sunali Goonesekera, Giovanni Caponetti, Jerry Sadoff, Barry R Bloom, David Edwards.   

Abstract

With the increasing incidence of tuberculosis and drug resistant disease in developing countries due to HIV/AIDS, there is a need for vaccines that are more effective than the present bacillus Calmette-Guérin (BCG) vaccine. We demonstrate that BCG vaccine can be dried without traditional freezing and maintained with remarkable refrigerated and room-temperature stability for months through spray drying. Studies with a model Mycobacterium (Mycobacterium smegmatis) revealed that by removing salts and cryoprotectant (e.g., glycerol) from bacterial suspensions, the significant osmotic pressures that are normally produced on bacterial membranes through droplet drying can be reduced sufficiently to minimize loss of viability on drying by up to 2 orders of magnitude. By placing the bacteria in a matrix of leucine, high-yield, free-flowing, "vial-fillable" powders of bacteria (including M. smegmatis and M. bovis BCG) can be produced. These powders show relatively minor losses of activity after maintenance at 4 degrees C and 25 degrees C up to and beyond 4 months. Comparisons with lyophilized material prepared both with the same formulation and with a commercial formulation reveal that the spray-dried BCG has better overall viability on drying.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17299039      PMCID: PMC1815227          DOI: 10.1073/pnas.0611430104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

1.  Formulation and physical characterization of large porous particles for inhalation.

Authors:  R Vanbever; J D Mintzes; J Wang; J Nice; D Chen; R Batycky; R Langer; D A Edwards
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

2.  Is the development of a new tuberculosis vaccine possible?

Authors:  S H Kaufmann
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

Review 3.  Tuberculosis vaccine development: recent progress.

Authors:  I M Orme; D N McMurray; J T Belisle
Journal:  Trends Microbiol       Date:  2001-03       Impact factor: 17.079

Review 4.  BCG vaccination against tuberculosis: past disappointments and future hopes.

Authors:  P W Roche; J A Triccas; N Winter
Journal:  Trends Microbiol       Date:  1995-10       Impact factor: 17.079

5.  An Aqueous Polymer Two-Phase System as Carrier in the Spray-Drying of Biological Material.

Authors: 
Journal:  J Colloid Interface Sci       Date:  2000-05-01       Impact factor: 8.128

6.  Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator.

Authors:  M Mumenthaler; C C Hsu; R Pearlman
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

7.  Long-term preservation and storage of mycobacteria.

Authors:  T H Kim; G P Kubica
Journal:  Appl Microbiol       Date:  1972-09
  7 in total
  20 in total

1.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  Formulation and stabilization of Francisella tularensis live vaccine strain.

Authors:  Satoshi Ohtake; Russell A Martin; Atul Saxena; David Lechuga-Ballesteros; Araceli E Santiago; Eileen M Barry; Vu Truong-Le
Journal:  J Pharm Sci       Date:  2011-04-13       Impact factor: 3.534

Review 3.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

4.  Immunization by a bacterial aerosol.

Authors:  Lucila Garcia-Contreras; Yun-Ling Wong; Pavan Muttil; Danielle Padilla; Jerry Sadoff; Jessica Derousse; Willem Andreas Germishuizen; Sunali Goonesekera; Katharina Elbert; Barry R Bloom; Rich Miller; P Bernard Fourie; Anthony Hickey; David Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-14       Impact factor: 11.205

5.  New trends in resuscitation.

Authors:  Hasan B Alam; George C Velmahos
Journal:  Curr Probl Surg       Date:  2011-08       Impact factor: 1.909

6.  Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.

Authors:  Elena V Vassilieva; Haripriya Kalluri; Devin McAllister; Misha T Taherbhai; E Stein Esser; Winston P Pewin; Joanna A Pulit-Penaloza; Mark R Prausnitz; Richard W Compans; Ioanna Skountzou
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 4.617

7.  Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate.

Authors:  Samantha L Sampson; Keith G Mansfield; Angela Carville; D Mitchell Magee; Teresa Quitugua; Elizabeth W Howerth; Barry R Bloom; Mary K Hondalus
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

8.  A stable live bacterial vaccine.

Authors:  Nitesh K Kunda; Denis Wafula; Meilinn Tram; Terry H Wu; Pavan Muttil
Journal:  Eur J Pharm Biopharm       Date:  2016-03-25       Impact factor: 5.571

Review 9.  Microneedle patches for vaccination in developing countries.

Authors:  Jaya Arya; Mark R Prausnitz
Journal:  J Control Release       Date:  2015-11-18       Impact factor: 9.776

10.  Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.

Authors:  Mark T Orr; Elyse A Beebe; Thomas E Hudson; David Argilla; Po-Wei D Huang; Valerie A Reese; Christopher B Fox; Steven G Reed; Rhea N Coler
Journal:  Vaccine       Date:  2015-11-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.